Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
High Ahfam,
looking through and cross referencing ie Covid 10, Interleukins, granulyte macrophage colony stimulating factor, macrophages, CD4 positive cells T helper cells) CD4 (T killer cells) there is also a regulator cell too, and this is decided by Interferon gamma, Interferons, STAT pathways, Tyk 2 inhibitors Jak 1, 2 and 3 inhibitors and many other subjects mainly from Wikipedia which is pretty well up to date.
Tyk 2 also regulate IL-7 and IL-12 ( IL-12) will signal Interferon gamma. Tyk 2 signals via STAT 5 pathway whilst Jak1 signals via STAT 3 pathway'
All looks very very very promising. Tyk 2 has limited targets and hence can be made far more selective. JAK 3 reacts with too many Interleukins!. JAk 3 also requires Jak 1( Jak 3 requires Jak 1 to work in partnership or will not work at all)
Jak1 and Jak 3 only inhibitors will run the risk of very high risk of serious side effects ( That is why they have had NDA issued black box warnings)
JAK 2 is effective but here again reacts with too many Interferons etc, and hence has side effects due to interferon production of which we need, being halted and hence counter productive. More associated health risks with this one.
TYK2 more selective thanJAK 2 without associated side effects.
I have cross referenced with the description of our patented TYK2 and my current conclusion, so far is looking good to satisfy CTA requirements.
One thing I have concluded is
There does not exist a first generation of JAK 1, Jak 2 or JAK or any combination that will be suitable to treat immuno diseases sucessfullly due to the above lack of selectivity.
As far as I can see, and someone please correct me if I am wrong, that we have certainly no serious competition in any shape or form,with regards to not only Covid19 but also the original targets of intent.
Regards all
Bang on Sad and together with the patents we are primed for something truly extraordinary and AIM and the crowd will see to it that it happens. And we say Sar are not a leaky ship but with so much money to be made you'll be surprised what people can find out.
I can find no elevated levels of IL-1 with respect to Covid 19 in Wikipedia
I will add. I think the ball is in the back of the net!
GM-CSF covered by TYK 2 and Jak 1 indirectly.
All cute and of course no toxicity from a JAK 2 but much more selective with TYK 2 and the magic dash
of JAK 1
Regards
Hi Ahfam from October 2010, Just a reminder
There is substantial evidence in the scientific literature to suggest that inhibitors of TYK2/JAK1 signalling could address the severe inflammatory responses (the "cytokine storm") and potentially fatal respiratory symptoms of Covid-19 and other viral infections.
Several clinical trials with JAK kinase inhibitors have been started to investigate the potential of targeting this pathway as a therapeutic approach. On 8 October 2020, Eli Lilly & Co. reported promising data from its Phase 3 trials of baricitinib, which inhibits JAK1/JAK2 kinase-mediated cytokine release, in hospitalised Covid-19 patients. The data showed that baricitinib in combination with the anti-viral drug remdesivir significantly reduced the time to recovery vs remdesivir alone, particularly in patients that required supplemental oxygen. Mortality was also decreased, again more pronounced in patients receiving oxygen.
Sareum has applied for grant funding to conduct preliminary laboratory studies investigating the ability of its TYK2/JAK1 inhibitors to modulate (down-regulate) the overactive immune system in relevant cellular and mouse disease models.
From recent Patent description
The non-receptor tyrosine kinase TYK2 plays essential roles in both innate and adaptive immunity. A lack of TYK2 expression manifests in the attenuated signalling of multiple proinflammatory cytokines and a profound imbalance in T helper cell differentiation. Furthermore, evidence from genetic association studies supports that TYK2 is a shared autoimmune disease susceptibility gene. Taken together, these reasons suggest TYK2 as a target for the treatment of inflammatory and auto-immune diseases.
Several JAK family inhibitors have been reported in the literature which may be useful in the medical field ( Ghoreschi et al, 2009. Immunol Rev, 228:273-287 ). It is expected that a selective TYK2 inhibitor that inhibits TYK2 with greater potency than JAK2 may have advantageous therapeutic properties, because inhibition of JAK2 can cause anemia ( Ghoreschi et al, 2009. Nature Immunol. 4, 356-360 ).
Even though TYK2 inhibitors are known in the art there is a need for providing additional TYK2 inhibitors having at least partially more effective pharmaceutically relevant properties, like activity, selectivity especially over JAK2 kinase, and ADMET properties. Thus, an object of the present invention is to provide a new class of compounds as TYK2 inhibitors which preferably show selectivity over JAK2 and may be effective in the treatment or prophylaxis of disorders associated with TYK2.
Covid 19 causes of cytokine storm ( source wikipedia)
IL-1, IL-2, IL-6, Interferon gamma and TNF alpha.
IL-2, IL-6 covered by Tyk 2 , TNA alpha along with IL-10 and type 2 interferon ( of which there is only one interferon gamma covered by JAK1.
Not sure about IL-1. Tired and sleep time. But the above looks extremely promising so far amd GS-CSF controlled by
https://www.nature.com/articles/d41586-021-01090-z
Thanks BoilB !
Bloody hell if the WHO are now going auto-immune it says it all- if we get even slightest good covid data we're going gangbusters chaps.
Remember in the half yearly results Dr Tim said 'If this study continues to be successful, it may allow us to apply for further non-dilutive government funding from the recently announced AGILE platform to advance this programme into clinical trials'
And Dr Parker added in his statetment 'Initial studies, using isolated human lung cells, are encouraging and show that SDC-1801 does indeed downregulate the increase in cytokines believed to be responsible for ARDS and the cytokine storm following infection with SARS-CoV-2'.
The signs are there chaps Dr Tim saying 'if it continues to be successful' meaning it has been insofar and Dr Parker saying 'does indeed downregulate the increase in cytokines' meaning it works.
Indeed indeed we are in for a ride like we have never experienced before FOMO is an understatement- many happy returns chaps.
just re-read that article, hairs up on back of my neck, felt bit sick, then realised, this is now potentially the real deal!!!
No new competition, except the Chinese black market lol
Charlie and the chocolate factory, I've got my ticket;)
weeks now, not years fellow LTH's ;)
That’s a great idea use the 4 drugs that have proven nothing and I take it none use tyk2 jak 1 It’s about time the WHO heard of Sareum
Its a massive market, WHO are desperate AIMOHO... Same old drugs....;) bring on the newbies...
https://www.greaterkashmir.com/news/front-page-2/who-to-restart-covid-drug-trial-with-focus-on-immune-responses/
GLALTH's